RESUMEN
The limitations of platinum in ovarian cancer therapy, such as poor solubility and significant side effects, often lead to suboptimal therapeutic outcome and mortality. In this study, we have developed a novel approach utilizing biodegradable polymeric nanoparticles as a drug delivery system (NDDS), loaded with advanced platinum (IV) (Pt(IV)) prodrugs. A key feature of our approach is the enhancement of nanoparticles with maleimide, a modification hypothesized to significantly boost tumor tissue accumulation. When tested in mouse models of orthotopic and peritoneal metastasis ovarian cancer, these maleimide-modified nanoparticles are anticipated to show preferential accumulation in tumor tissues, enhancing therapeutic efficiency and minimizing systemic drug exposure. Our findings demonstrate that the maleimide-modified Pt(IV)-loaded NDDSs significantly reduce tumor burden in comparison to traditional cisplatin therapy, while simultaneously reducing adverse side effects. This leads to markedly improved survival rates in models of peritoneal metastasis ovarian cancer, offering a promising new direction in the treatment of this challenging disease.
RESUMEN
We investigate dynamic signatures of the singlet fission (SF) process triggered by the excitation of a molecular system to an upper singlet state SN (N > 1) and develop a computational methodology for the simulation of nonlinear spectroscopic signals revealing the SN â TT1 SF in real time. We demonstrate that SF can proceed directly from the upper state SN, bypassing the lowest excited state, S1. We determine the main SN â TT1 reaction pathways and show by computer simulation and spectroscopic measurements that the SN-initiated SF can be faster and more efficient than the traditionally studied S1 â TT1 SF. We claim that the SN â TT1 SF offers novel promising opportunities for engineering SF systems and enhancing SF yields.